# Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma

> **NCT00509184** · PHASE2 · COMPLETED · sponsor: **Klaus Herfarth, MD** · enrollment: 85 (actual)

## Conditions studied

- Lymphoma, Malignant

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00509184
- **Lead sponsor:** Klaus Herfarth, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2020-01-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509184, "Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00509184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*